DEF 14A: Lucid Diagnostics Inc. to Hold Annual Stockholders Meeting on June 20, 2024

Lucid Diagnostics Inc. will hold its annual stockholders meeting virtually on June 20, 2024, to vote on director elections, stock issuance approval, and accountant ratification.

Summary

• Lucid Diagnostics Inc. is holding its annual meeting of stockholders on June 20, 2024, virtually.
• Stockholders will vote on three proposals: electing two Class C directors, approving the issuance of common stock under the Series B Convertible Preferred Stock, and ratifying the appointment of Marcum LLP as the independent registered certified public accounting firm.
• The record date for determining stockholders eligible to vote is April 22, 2024.
• As of the record date, there were 49,784,461 shares of common stock outstanding and 44,285 shares of Series B Preferred Stock outstanding, convertible into 7,469,030 shares of common stock.
• PAVmed Inc. holds approximately 59.2% of the Company's outstanding capital stock and intends to vote in favor of all management proposals.
• The Board recommends voting FOR the election of directors, FOR the stock issuance proposal, and FOR the accountant ratification proposal.

Sentiment

Score: 6

Explanation: The document is primarily procedural, outlining the agenda for the annual meeting and seeking approval for routine matters. The potential dilution from the stock issuance is a slight negative, but overall the tone is neutral.

Positives

• The Board is recommending stockholders vote in favor of all proposals.
• PAVmed, the controlling stockholder, intends to vote in favor of all proposals.
• The Company has a code of ethics that applies to all of its executive officers, directors and employees.
• The Company has determined that each of Drs. Cox and Sokolov, Messrs. Lapidus and Sparks and Ms. White is an independent director.

Negatives

• The issuance of shares pursuant to the Series B Preferred Stock will have a dilutive effect on the existing stockholders, including on the voting power and economic rights of the existing stockholders, and may result in a decline in the price of the Company's common stock or in greater price volatility.
• If the Stock Issuance Proposal is not approved, the Company may not be able to satisfy all conversions under the Series B Preferred Stock, which may negatively impact its ability to raise capital in the future.
• PAVmed's controlling interest may discourage a change of control that other holders of the Company's stock may favor.

Risks

• Failure to obtain stockholder approval for the Stock Issuance Proposal could limit the Company's ability to issue shares upon conversion of the Series B Preferred Stock, potentially hindering future capital raising efforts.
• The Company is dependent on PAVmed for management and administrative services, and any disruption in this relationship could negatively impact operations.
• The Company's officers and directors have fiduciary obligations to other companies, including PAVmed, which could create conflicts of interest.
• The Company is subject to Section 203 of the DGCL, which could make it more difficult to acquire the Company.

Future Outlook

The Company may offer up to an additional 11,835 shares of Series B Preferred Stock for aggregate gross proceeds of up to $11,835,000, with a conversion price equal to the average volume-weighted average price of the Company's common stock on the five trading days immediately preceding the date of the applicable closing, but not less than $0.60 or after September 20, 2024.

Management Comments

• PAVmed has indicated that it intends to vote FOR the management nominees in the Director Election Proposal, FOR the Stock Issuance Proposal and FOR the Accountant Ratification Proposal.

Industry Context

The document reflects standard corporate governance procedures for publicly traded companies, including the holding of annual meetings, election of directors, and ratification of auditors. The proposed stock issuance is a common method for raising capital, particularly for companies in the growth phase.

Comparison to Industry Standards

• The structure of the board with classified directors is a common practice, although some governance experts advocate for declassified boards to enhance accountability.
• The compensation arrangements for executive officers and directors appear to be within the typical range for companies of similar size and stage of development, but a detailed benchmarking analysis would be required to confirm this.
• The related party transactions with PAVmed are extensive, which is not uncommon for spin-off companies, but require careful scrutiny to ensure they are on arm's-length terms.
• The auditor ratification process is a standard practice, and the fees paid to Marcum LLP are within the expected range for a company of this size.

Related Party Transactions

• The Company has a management services agreement with PAVmed, paying $833,333 per month as of January 1, 2024.
• The Company has a payroll and benefit expense reimbursement agreement with PAVmed.
• The Company licensed intellectual property rights from PAVmed related to esophageal ablation technology.
• PAVmed Subsidiary Corp. assigned 100% of the equity interests of CapNostics, LLC to the Company.

Stakeholder Impact

• Approval of the stock issuance proposal will allow the Company to raise capital, potentially benefiting shareholders in the long term, but may dilute existing holdings.
• The election of directors will determine the leadership and strategic direction of the Company.
• The ratification of the auditor ensures the integrity of the Company's financial reporting.

Next Steps

• Stockholders should review the proxy materials and vote on the proposals.
• The Company will hold the Annual Meeting on June 20, 2024, and announce the results of the voting.
• The Company will continue to seek stockholder approval of the Stock Issuance Proposal until it obtains such approval.

Key Dates

Keywords

stockholders meeting, proxy statement, director election, stock issuance, Series B Preferred Stock, accountant ratification, Marcum LLP, PAVmed, corporate governance, Lucid Diagnostics